Cannabinoids and viral infections

Pharmaceuticals

Volumn 3, Issue 6, 2010, Pages 1873-1886

  Reiss, Carol Shoshkes ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Immunomodulation; Inflammation; Pathogens; Virus infection

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CALCIUM ION; CANNABINOID; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; NEURONAL NITRIC OXIDE SYNTHASE; OMDM 1; OMDM 2; PALMIDROL; SR 144558; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BORNA DISEASE VIRUS; CANCER PAIN; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG MECHANISM; ENZYME ACTIVATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOREGULATION; INFLAMMATION; MOTOR DYSFUNCTION; MYCOSIS; NERVE CELL; NONHUMAN; PARASITOSIS; REVIEW; VIRUS CELL INTERACTION; VIRUS INFECTION;

EID: 77954928704     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3061873     Document Type: Review

References (86)

1. Bannenberg, G.L.; Chiang, N.; Ariel, A.; Arita, M.; Tjonahen, E.; Gotlinger, K.H.; Hong, S.; Serhan, C.N.ti Molecular circuits of resolution: Formation and actions of resolvins and protectins. J. Immunol. 2005, 174, 4345-4355.
2. Machado, F.S.; Johndrow, J.E.; Esper, L.; Dias, A.; Bafica, A.; Serhan, C.N.; Aliberti, J. Anti- inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 2006, 12, 330-334.
3. Morita, M.; Yoshiki, F.; Nakane, A.; Okubo, Y.; Kudo, Y. Receptor- and calcium-dependent induced inositol 1,4,5-trisphosphate increases in PC12h cells as shown by fluorescence resonance energy transfer imaging. FEBS J. 2007, 274, 5147-5157.
4. Vitale, N. Synthesis of fusogenic lipids through activation of phospholipase D1 by GTPases and the kinase RSK2 is required for calcium-regulated exocytosis in neuroendocrine cells. Biochem. Soc. Trans. 2010, 38, 167-171.
5. Oh-hora, M.; Rao, A. The calcium/NFAT pathway: Role in development and function of regulatory T cells. Microbes Infect. 2009, 11, 612-619.
6. Rao, A. Signaling to gene expression: Calcium, calcineurin and NFAT. Nat. Immunol. 2009, 10, 3-5.
7. Knowles, R.G.; Moncada, S. Nitric oxide synthases in mammals. Biochem. J. 1994, 298, 249-258.
8. Lopez-Jaramillo, P.; Teran, E.; Moncada, S. Calcium supplementation prevents pregnancy- induced hypertension by increasing the production of vascular nitric oxide. Med. Hypotheses 1995, 45, 68-72.
9. Edelstein, C.L.; Yaqoob, M.M.; Schrier, R.W. The role of the calcium-dependent enzymes nitric oxide synthase and calpain in hypoxia-induced proximal tubule injury. Ren Fail. 1996, 18, 501-511.
10. Reiss, C.S.; Komatsu, T. Does nitric oxide play a critical role in viral infections? J. Virol. 1998, 72, 4547-4551.
11. Akaike, T.; Maeda, H. Nitric oxide and virus infection. Immunology 2000, 101, 300-308.
12. Akuta, T.; Zaki, M.H.; Yoshitake, J.; Okamoto, T.; Akaike, T. Nitrative stress through formation of 8-nitroguanosine: Insights into microbial pathogenesis. Nitric. Oxide. 2006, 14, 101-108.
13. Alvania, R.S.; Chen, X.; Ginty, D.D. Calcium signals control Wnt-dependent dendrite growth. Neuron 2006, 50, 813-815.
14. Wayman, G.A.; Impey, S.; Marks, D.; Saneyoshi, T.; Grant, W.F.; Derkach, V.; Soderling, T.R. Activity-dependent dendritic arborization mediated by CaM-kinase I activation and enhanced CREB-dependent transcription of Wnt-2. Neuron 2006, 50, 897-909.
15. Flaherty, M.P.; Dawn, B. Noncanonical Wnt11 signaling and cardiomyogenic differentiation. Trends Cardiovasc. Med. 2008, 18, 260-268.
16. Caplan, M.J.; Seo-Mayer, P.; Zhang, L. Epithelial junctions and polarity: Complexes and kinases. Curr. Opin. Nephrol. Hypertens. 2008, 17, 506-512.
17. Liu, J.O. Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation. Immunol. Rev. 2009, 228, 184-198.
18. Pontremoli, S.; Melloni, E. Extralysosomal protein degradation. Annu. Rev Biochem. 1986, 55, 455-481.
19. Mellgren, R.L. Calcium-dependent proteases: An enzyme system active at cellular membranes? FASEB J. 1987, 1, 110-115.
20. Dargelos, E.; Poussard, S.; Brule, C.; Daury, L.; Cottin, P. Calcium-dependent proteolytic system and muscle dysfunctions: a possible role of calpains in sarcopenia. Biochimie 2008, 90, 359-368.
21. Consolo, M.; Amoroso, A.; Spandidos, D.A.; Mazzarino, M.C. Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int. J. Mol. Med. 2009, 24, 143-152.
22. Rojas, F.J.; Brush, M.; Moretti-Rojas, I. Calpain-calpastatin: A novel, complete calcium- dependent protease system in human spermatozoa. Mol. Hum. Reprod. 1999, 5, 520-526.
23. Elli, L.; Bergamini, C.M.; Bardella, M.T.; Schuppan, D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig. Liver Dis. 2009, 41, 541-550.
24. Reiss, C.S. Innate immunity in viral encephalitis. In Neurotropic Virus Infections. Cambridge University Press: Cambridge, UK, 2008, pp. 265-291.
25. Reiss, C.S. VSV infection elicits distinct host responses in the periphery and the brain. In RNA Viruses: Host Gene Responses to Infection; Yang, D., ed. World Scientific Publishing: Hackensack, NJ, USA, 2009; pp. 229-246.
26. Klein, T.W.; Friedman, H.; Specter, S. Marijuana, immunity and infection. J. Neuroimmunol. 1998, 83, 102-115.
27. Bani, D.; Mannaioni, G.; Passani, M.B.; Masini, E. Role of cannaboboids in the modulation f inflammatory processes. Pharmaceuticals 2010, submitted.
28. Klein, T.W.; Cabral, G.A. Cannabinoid-induced immune suppression and modulation of antigen- presenting cells. J. Neuroimmune. Pharmacol. 2006, 1, 50-64.
29. Morahan, P.S.; Klykken, P.C.; Smith, S.H.; Harris, L.S.; Munson, A.E. Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect. Immun. 1979, 23, 670-674.
30. Mishkin, E.M.; Cabral, G.A. Delta-9-Tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J. Gen. Virol. 1985, 66, 2539-2549.
31. Cabral, G.A.; Lockmuller, J.C.; Mishkin, E.M. Delta 9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc. Soc. Exp. Biol. Med. 1986, 181, 305-311.
32. Cabral, G.A.; Mishkin, E.M.; Marciano-Cabral, F.; Coleman, P.; Harris, L.; Munson, A.E. Effect of delta 9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infection in the guinea pig. Proc. Soc. Exp. Biol. Med. 1986, 182, 181-186.
33. Blevins, R.D.; Dumic, M.P. The effect of delta-9-tetrahydrocannabinol on herpes simplex virus replication. J. Gen. Virol. 1980, 49, 427-431.
34. Cabral, G.A.; McNerney, P.J.; Mishkin, E.M. Delta-9-tetrahydrocannabinol enhances release of herpes simplex virus type 2. J. Gen. Virol. 1986, 67, 2017-2022.
35. Cabral, G.A.; McNerney, P.J.; Mishkin, E.M. Delta-9-tetrahydrocannabinol inhibits the splenocyte proliferative response to herpes simplex virus type 2. Immunopharmacol. Immunotoxicol. 1987, 9, 361-370.
36. Lancz, G.; Specter, S.; Brown, H.K. Suppressive effect of delta-9-tetrahydrocannabinol on herpes simplex virus infectivity in vitro. Proc. Soc. Exp. Biol. Med. 1991, 196, 401-404.
37. Fischer-Stenger, K.; Updegrove, A.W.; Cabral, G.A. Delta 9-tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells. Proc. Soc. Exp. Biol. Med. 1992, 200, 422-430.
38. Medveczky, M.M.; Sherwood, T.A.; Klein, T.W.; Friedman, H.; Medveczky, P.G. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC. Med. 2004, 2, 34.
39. Zhang, X.; Wang, J.F.; Kunos, G.; Groopman, J.E. Cannabinoid modulation of Kaposi's sarcoma- associated herpesvirus infection and transformation. Cancer Res. 2007, 67, 7230-7237.
40. Huemer, H.P.; Himmelreich, A.; Honlinger, B.; Pavlic, M.; Eisendle, K.; Hopfl, R.; Rabl, W.; Czerny, C.P. Recreational drug abuse associated with failure to mount a proper antibody response after a generalised orthopoxvirus infection. Infection 2007, 35, 469-473.
41. Molina-Holgado, F.; Lledo, A.; Guaza, C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 1997, 8, 1929-1933.
42. Oleszak, E.L.; Katsetos, C.D.; Kuzmak, J.; Varadhachary, A. Inducible nitric oxide synthase in Theiler's murine encephalomyelitis virus infection. J. Virol. 1997, 71, 3228-3235.
43. Molina-Holgado, F.; Molina-Holgado, E.; Guaza, C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. 1998, 433, 139-142.
44. Croxford, J.L.; Miller, S.D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212. J. Clin. Invest. 2003, 111, 1231-1240.
45. Mestre, L.; Correa, F.; Arevalo-Martin, A.; Molina-Holgado, E.; Valenti, M.; Ortar, G.; Di Marzo, V.; Guaza, C. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 2005, 92, 1327-1339.
46. Correa, F.; Mestre, L.; Docagne, F.; Guaza, C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: Role of IL-10 and ERK1/2 kinase signaling. Br. J. Pharmacol. 2005, 145, 441-448.
47. Mestre, L.; Correa, F.; Docagne, F.; Clemente, D.; Guaza, C. The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem. Pharmacol. 2006, 72, 869-880.
48. Loria, F.; Petrosino, S.; Mestre, L.; Spagnolo, A.; Correa, F.; Hernangomez, M.; Guaza, C.; Di Marzo, V.; Docagne, F. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci 2008, 28, 633-641.
49. Mestre, L.; Docagne, F.; Correa, F.; Loria, F.; Hernangomez, M.; Borrell, J.; Guaza, C. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell. Neurosci. 2009, 40, 258-266.
50. Buchweitz, J.P.; Karmaus, P.W.; Harkema, J.R.; Williams, K.J.; Kaminski, N.E. Modulation of airway responses to influenza A/PR/8/34 by Delta9-tetrahydrocannabinol in C57BL/6 mice. J. Pharmacol. Exp. Ther. 2007, 323, 675-683.
51. Buchweitz, J.P.; Karmaus, P.W.; Williams, K.J.; Harkema, J.R.; Kaminski, N.E. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol. J. Leukoc. Biol. 2008, 83, 785-796.
52. Herrera, R.A.; Oved, J.H.; Reiss, C.S. Disruption of the IFN-g-mediated antiviral activity in neurons: The role of Cannabinoids. Viral Immunol. 2008, 21, 141-152.
53. Solbrig, M.V.; Hermanowicz, N. Cannabinoid rescue of striatal progenitor cells in chronic Borna disease viral encephalitis in rats. J. Neurovirol. 2008, 14, 252-260.
54. Hezode, C.; Roudot-Thoraval, F.; Nguyen, S.; Grenard, P.; Julien, B.; Zafrani, E.S.; Pawlotsky, J.M.; Dhumeaux, D.; Lotersztajn, S.; Mallat, A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005, 42, 63-71.
55. Costiniuk, C.T.; Mills, E.; Cooper, C.L. Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can. J. Gastroenterol. 2008, 22, 376-380.
56. Ishida, J.H.; Peters, M.G.; Jin, C.; Louie, K.; Tan, V.; Bacchetti, P.; Terrault, N.A. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol. Hepatol. 2008, 6, 69-75.
57. Noe, S.N.; Nyland, S.B.; Ugen, K.; Friedman, H.; Klein, T.W. Cannabinoid receptor agonists enhance syncytia formation in MT-2 cells infected with cell free HIV-1MN. Adv. Exp. Med. Biol. 1998, 437, 223-229.
58. Stefano, G.B.; Salzet, M.; Bilfinger, T.V. Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: Uncoupling of nitric oxide release. J. Cardiovasc. Pharmacol. 1998, 31, 862-868.
59. Esposito, G.; Ligresti, A.; Izzo, A.A.; Bisogno, T.; Ruvo, M.; Di Rosa, M.; Di Marzo, V.; Iuvone, T. The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity: Mechanism and regulation. J. Biol. Chem. 2002, 277, 50348-50354.
60. Bredt, B.M.; Higuera-Alhino, D.; Shade, S.B.; Hebert, S.J.; McCune, J.M.; Abrams, D.I. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J. Clin. Pharmacol. 2002, 42, 82S-89S.
61. Abrams, D.I.; Hilton, J.F.; Leiser, R.J.; Shade, S.B.; Elbeik, T.A.; Aweeka, F.T.; Benowitz, N.L.; Bredt, B.M.; Kosel, B.; Aberg, J.A., et al. Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. Ann. Intern. Med. 2003, 139, 258-266.
62. Peterson, P.K.; Gekker, G.; Hu, S.; Cabral, G.; Lokensgard, J.R. Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. J. Neuroimmunol. 2004, 147, 123-126.
63. Roth, M.D.; Tashkin, D.P.; Whittaker, K.M.; Choi, R.; Baldwin, G.C. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci. 2005, 77, 1711-1722.
64. Lu, T.S.; Avraham, H.K.; Seng, S.; Tachado, S.D.; Koziel, H.; Makriyannis, A.; Avraham, S. Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J. Immunol. 2008, 181, 6406-6416.
65. Benamar, K.; Yondorf, M.; Meissler, J.J.; Geller, E.B.; Tallarida, R.J.; Eisenstein, T.K.; Adler, M.W. A novel role of cannabinoids: Implication in the fever induced by bacterial lipopolysaccharide. J. Pharmacol. Exp. Ther. 2007, 320, 1127-1133.
66. 2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 2010, [doi: 10.1124/jpet.109.163055].
67. Jakob, J.; Roos, R.P. Molecular determinants of Theiler's murine encephalomyelitis-induced disease. J. Neurovirol. 1996, 2, 70-77.
68. Olson, J.K.; Miller, S.D. The innate immune response affects the development of the autoimmune response in Theiler's virus-induced demyelinating disease. J. Immunol. 2009, 182, 5712-5722.
69. Villarreal, D.; Young, C.R.; Storts, R.; Ting, J.W.; Welsh, C.J. A comparison of the neurotropism of Theiler's virus and poliovirus in CBA mice. Microb. Pathog. 2006, 41, 149-156.
70. Dietzschold, B.; Morimoto, K. Signaling pathways in virus-induced CNS inflammation. J. Neurovirol. 1997, 3 (Suppl. 1), S58-S59.
71. Gosztonyi, G.; Ludwig, H. Borna disease--neuropathology and pathogenesis. Curr. Top. Microbiol. Immunol. 1995, 190, 39-73.
72. Hooper, D.C.; Kean, R.B.; Scott, G.S.; Spitsin, S.V.; Mikheeva, T.; Morimoto, K.; Bette, M.; Rohrenbeck, A.M.; Dietzschold, B.; Weihe, E. The central nervous system inflammatory response to neurotropic virus infection is peroxynitrite dependent. J. Immunol. 2001, 167, 3470-3477.
73. Rohrenbeck, A.M.; Bette, M.; Hooper, D.C.; Nyberg, F.; Eiden, L.E.; Dietzschold, B.; Weihe, E. Upregulation of COX-2 and CGRP expression in resident cells of the Borna disease virus-infected brain is dependent upon inflammation. Neurobiol. Dis. 1999, 6, 15-34.
74. Cabral, G.A.; Dove Pettit, D.A. Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease. J. Neuroimmunol. 1998, 83, 116-123.
75. Munckhof, W.J.; Konstantinos, A.; Wamsley, M.; Mortlock, M.; Gilpin, C. A cluster of tuberculosis associated with use of a marijuana water pipe. Int. J Tuberc. Lung Dis. 2003, 7, 860-865.
76. Han, B.; Gfroerer, J.C.; Colliver, J.D. Associations between duration of illicit drug use and health conditions: Results from the 2005-2007 national surveys on drug use and health. Ann. Epidemiol. 2010, 20, 289-297.
77. Holtz, T.H.; Lancaster, J.; Laserson, K.F.; Wells, C.D.; Thorpe, L.; Weyer, K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int. J. Tuberc. Lung Dis. 2006, 10, 649-655.
78. Cabral, G.A.; Marciano-Cabral, F. Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J. Neuroimmunol. 2004, 147, 127-130.
79. Marciano-Cabral, F.; Raborn, E.S.; Martin, B.R.; Cabral, G.A. Delta-9-tetrahydrocannabinol, the major psychoactive component in marijuana, inhibits macrophage chemotaxis to Acanthamoeba. J. Eukaryot. Microbiol. 2006, 53 (Suppl. 1), S15-S17.
80. Benamar, K.; Yondorf, M.; Geller, E.B.; Eisenstein, T.K.; Adler, M.W. Physiological evidence for interaction between the HIV-1 co-receptor CXCR4 and the cannabinoid system in the brain. Br. J. Pharmacol. 2009, 157, 1225-1231.
81. Smith, S.R.; Terminelli, C.; Denhardt, G. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Eur. J. Pharmacol. 2001, 425, 73-83.
82. Bass, R.; Engelhard, D.; Trembovler, V.; Shohami, E. A novel nonpsychotropic cannabinoid, HU- 211, in the treatment of experimental pneumococcal meningitis. J. Infect. Dis. 1996, 173, 735-738.
83. Storr, M.A.; Yuce, B.; Andrews, C.N.; Sharkey, K.A. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol. Motil. 2008, 20, 857-868.
84. Storr, M.A.; Keenan, C.M.; Emmerdinger, D.; Zhang, H.; Yuce, B.; Sibaev, A.; Massa, F.; Buckley, N.E.; Lutz, B.; Goke, B., et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: Involvement of CB1 and CB2 receptors. J. Mol. Med. 2008, 86, 925-936.
85. Elikkottil, J.; Gupta, P.; Gupta, K. The analgesic potential of cannabinoids. J. Opioid. Manag. 2009, 5, 341-357.
86. Aggarwal, S.K.; Carter, G.T.; Sullivan, M.D.; ZumBrunnen, C.; Morrill, R.; Mayer, J.D. Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions. J. Opioid. Manag. 2009, 5, 153-168.